Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor

February 3, 2015 6:56 PM

12 0

(Reuters) - Pharmacy benefit manager Catamaran Corp said on Tuesday that it will back Gilead Sciences Inc's Harvoni and Sovaldi as exclusive hepatitis C treatments on its drug coverage lists.

Gilead has been striking deals with pharmacy benefit managers and insurers since AbbVie Inc late last year launched a competing product called Viekera Pak that produces similar high cure rates for hepatitis C.

Read more

To category page